1. Healthcare

  2. •

    Medical - Equipment & Services
Abaxis, Inc.

Abaxis, Inc.

ABAX
Abaxis, Inc.US flagNASDAQ
83.00
USD
- -
- -
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
TTM
Revenue per Share
3.45
4.18
4.68
4.84
5.66
6.42
7.09
8.48
7.72
9.01
9.66
10.09
- -
10.79
Basic EPS, GAAP
0.37
0.49
0.58
0.55
0.59
0.65
0.59
1.25
0.64
1.21
1.4
1.45
- -
1.2
Free Cash Flow per Basic Share
0.33
0.43
0.53
0.31
0.87
0.42
0.65
1.07
1.35
1.35
1.01
1.02
- -
1.65
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
1
- -
0.4
0.44
0.52
- -
0.6
Book Value per Share
-1.28
-0.75
-0.14
0.41
6.68
1.64
7.23
2.51
8.71
3.9
4.82
5.79
- -
12.83
Tangible Book Value per Share
3.53
4.23
4.85
5.58
6.47
7.35
7.05
7.89
8.63
9.72
10.37
11.77
- -
12.78
Basic Weighted Avg Shares
20
21
21
22
22
22
22
22
22
22
23
23
- -
23
Sales/Revenue/Turnover
69
86
101
106
125
144
157
186
172
203
219
227
- -
245
Operating Margin (%)
15.57
16.67
17.61
16.86
16.68
15.64
12.42
13.38
12.1
16.93
21.18
19.58
- -
15.8
Depreciation Expense
2
3
3
4
5
5
5
6
7
8
7
7
- -
8
Net Income, GAAP
7
10
13
12
13
15
13
27
14
27
32
33
- -
27
Effective Tax Rate (%)
35.11
37.62
36.87
36.99
39.16
38.33
35.09
35.22
35.36
37.04
34.09
35.87
- -
37.38
Profit Margin (%)
10.84
11.68
12.43
11.38
10.46
10.12
8.36
14.76
8.25
13.49
14.45
14.4
- -
11.11
Working Capital
50
75
52
102
89
108
110
133
149
169
183
200
220
220
LT Debt
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
- -
- -
- -
Total Equity
71
88
105
127
147
169
160
176
194
220
236
266
291
291
Return on Invested Capital (%)
10.49
11.29
11.62
9.68
9.21
8.73
7.64
9.54
7.21
10.27
13.21
11.28
- -
8.64
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
16.68
15.82
13.33
25.56
11.39
19.41
32.12
27.31
- -
12.91

Capital Structure

FRC

•

in mil. unless spec.
Sep'18
Dec'18
Mar'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
1,001
1,116
1,598

Working Capital

FRC

•

in mil. unless spec.
Sep'18
Dec'18
Mar'18
Total Current Assets
233
251
264
Cash, Cash Equivalents & STI
149
162
167
Accounts Receivable, Net
41
40
48
Inventories
39
42
44
Total Current Liabilities
37
42
44
Payables & Accruals
24
29
41
ST Debt
- -
- -
- -
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.96%
10.56%
9.19%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
53
56
53
57
219
2017
58
59
53
58
227
2018
58
59
60
68
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.31
0.34
0.35
0.39
1.4
2017
0.31
0.51
0.3
0.33
1.45
2018
0.28
0.29
0.19
0.44
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.11
0.11
0.11
0.11
0.44
2017
0.12
0.12
0.14
0.14
0.52
2018
0.14
0.14
0.16
0.16
- -

Company Description

APIChat
Sector
Healthcare
Industry
Medical - Equipment & Services
Address
IPO Date
Jan 23, 1992
CIK
0000881890
Similar Companies
Med-Design Corp. (The) (MEDC)
UBC Medical Indonesia Tbk. (LABS.JK)
Cegedim S.A. (0DYQ.L)
Abiomed, Inc. (0H7S.L)
Balaxi Pharmaceuticals Limited (BALAXI.NS)
Landauer Inc. (LDR)
Business
Abaxis, Inc. is a developer, manufacturer, and marketer of portable blood analysis systems and diagnostic instruments primarily serving the human medical and veterinary markets. Founded in 1989 and headquartered in Union City, California, the company produces a range of diagnostic products including the VetScan portfolio of benchtop and handheld diagnostic instruments, consumable discs, kits, and cartridges. These products enable rapid point-of-care blood constituent measurements and disease detection, supporting practices in efficiency and quality of care delivery. Abaxis’s offerings include chemistry analyzers like the Piccolo Xpress; hematology instruments for complete blood counts (CBC); rapid lateral flow tests such as the VetScan Canine Heartworm Rapid Test; and coagulation analyzers like the VetScan VSpro. The company sells its products through a direct sales force and independent distributors worldwide, with significant operations in North America, Europe, Latin America, and the Asia Pacific. A major recent change for Abaxis is its acquisition by Zoetis Inc. in 2018 for approximately $2.0 billion, which enhanced Zoetis’s presence in the veterinary diagnostics segment. This acquisition positions Abaxis within a larger global organization with extensive sales and customer relationships in approximately 45 countries. Since the acquisition, Abaxis has expanded its international operations, with about 20% of fiscal 2018 revenue coming from markets outside the U.S., and has maintained a strategic focus on innovation in point-of-care diagnostic technologies. The company continues to introduce new products enhancing its VetScan line and collaborates in research and development, such as its 2024 partnership with Blacksmith Medicines to discover and develop novel antibiotics for animal health. Abaxis operates primarily in the veterinary and human diagnostic industries, targeting veterinary practices, medical clinics, and research markets globally. It serves animal health professionals with diagnostic solutions for companion animals and farm animal care, fostering fast, onsite diagnostics that enable effective disease prediction, prevention, detection, and treatment. Abaxis is part of Zoetis, a global animal health company with a broad range of products sold in more than 100 countries, leveraging Zoetis’s sales platform to accelerate growth and expand market penetration. The company’s headquarters remain in Union City, California, continuing its mission to improve patient care through point-of-care diagnostics in both human and animal health sectors.